13-01-2025 | Metabolic Dysfunction-Associated Steatotic Liver Disease | Ischemic Heart Disease (D Mukherjee, Section Editor)
Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease
Authors:
Niki Katsiki, Genovefa Kolovou, Michal Vrablik
Published in:
Current Cardiology Reports
|
Issue 1/2025
Login to get access
Abstract
Purpose of Review
In recent years, the terms “metabolic associated fatty liver disease-MAFLD” and “metabolic dysfunction-associated steatotic liver disease-MASLD” were introduced to improve the encapsulation of metabolic dysregulation in this patient population, as well as to avoid the negative/stigmatizing terms “non-alcoholic” and “fatty”.
Recent Findings
There is evidence suggesting links between MASLD and coronary heart disease (CHD), heart failure (HF), atrial fibrillation (AF), stroke, peripheral artery disease (PAD) and chronic kidney disease (CKD), although the data for HF, AF, stroke and PAD are scarcer.
Summary
Physicians should consider the associations between MASLD and CV diseases in their daily practice. Based on this knowledge and current guidelines, they should also assess and manage CV risk/co-morbidities in such patients. It is important to further investigate the impact of MASLD on CV outcomes, a knowledge that will help to elucidate the clinical implications of this “novel” liver entity.